Funding · Healthcare & Life Sciences

Biodimension raises ₹8 crore from IAN Angel Fund

By Startup Enthusiast · 11 June 2026

What they do

Biodimension makes lab-grown human tissue and organ models that replace animal testing

It raised ₹8 crore in a round led by IAN Angel Fund, with Campus Angels Network and angel investors

The company plans to expand its cancer biobank and scale its on-demand testing service

Biodimension raised ₹8 crore in a funding round led by IAN Angel Fund.
Existing investor Campus Angels Network also participated in the round.
Angel investors Dr. Sampath Srisailam and Aaryan Baid joined the round.
The company will use the funds to accelerate product development and expand laboratory infrastructure.
It will also strengthen its scientific and commercial teams to drive commercialization in India and abroad.
Biodimension plans to expand its Pan-Cancer Tumour Microenvironment Biobank and add new oncology models.
It aims to scale its Bioassay-as-a-Service platform and expand into Southeast Asia, Europe, the US, and Japan.

India imports most of its human tissue testing models even though it is a large pharma manufacturing hub.
Biodimension's locally made models meet global regulatory standards and are cheaper and quicker for Indian researchers to obtain.
This funding supports the company's effort to offer homegrown alternatives to imported testing products.

Biodimension creates lab-grown human tissue and organ models that serve as ethical substitutes for animal testing.
Its customers include pharmaceutical, biotech, and cosmetic research companies.
Key products are BioDEpi (a reconstructed human skin layer for safety tests), BioDFT (a full-thickness skin model), and BioDPigma (a pigmented skin model).
It also runs a Pan-Cancer Tumour Microenvironment Biobank for cancer drug research.
The company offers a Bioassay-as-a-Service (BaaS) platform that performs on-demand human-relevant tests.
Biodimension works with pharma companies, biotech firms, research institutes, and contract research organizations in India and Singapore.
Its headquarters are in Bengaluru, India.

Accelerate product development and expand laboratory infrastructure.
Strengthen scientific and commercial teams.
Drive commercialization in India and international markets.
Expand Pan-Cancer Tumour Microenvironment Biobank and add new oncology and immunotherapy models.
Scale Bioassay-as-a-Service platform.
Expand across Southeast Asia and build partnerships in Europe, the US, and Japan.

IAN Angel Fund (lead) — Evergreen fund of IAN Group, an Indian angel investor network.
Campus Angels Network (participated) — Existing investor in Biodimension.
Dr. Sampath Srisailam (participated) — Angel investor.
Aaryan Baid (participated) — Angel investor.

Product: Human tissue models, organoids, and bioassay-as-a-service including BioDEpi, BioDFT, BioDPigma and pan-cancer tumor microenvironment biobank
Customers: Pharmaceutical, biotechnology and cosmetic companies requiring safety testing
How it makes money: Bioassay-as-a-service and licensing of tissue models
What sets it apart: Lab-grown tissue models that accurately replicate human responses for drug testing
Operations: Laboratory infrastructure for tissue fabrication and testing services